Epigral Ltd announced a 13% increase in net profit, reaching ₹87 crore for Q4 FY2025, with total revenue rising 20% to ₹631 crore compared to the same quarter last year, and proposed a total dividend of ₹6 per share for FY2025. The company is also expanding its capacity for CPVC and Epichlorohydrin, expected to be operational in FY2027.